We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Another offseason of speculation regarding Aaron Rodgers begins. The New York Jets quarterback ended the 2024 regular season – a disastrous campaign in which the head coach and general manager ...

VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...

They soon will begin interviewing for his replacement. They have scheduled an interview with former Jets defensive line Aaron Whitecotton, Ian Rapoport of NFL Media reports. Whitecotton spent four ...

Aaron Rodgers has spoken with the New York Jets to discuss his future, but many uncertainties remain. The Jets are in the midst of searching for a new general manager and head coach, adding ...

The local high school basketball community is mourning the death of Aaron Etherington, a former star player at Hamilton Southeastern. Etherington, 25, died unexpectedly on Tuesday. His father ...

Don't expect any major decisions from Aaron Rodgers anytime soon. The New York Jets quarterback spoke with “The Pat McAfee Show” on Thursday, saying that he's in a holding pattern for his own ...

Get Pro-Level Earnings Insights Before the Market Moves In a court filing on Monday, the Department of Health and Human Services (HHS) challenged Vertex Pharmaceuticals Inc VRTX, defending its ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth ...